Emerging resistance to antimicrobial agents in gram-positive bacteria: Enterococci, staphylococci and nonpneumococcal streptococci

Drugs

Volumn 51, Issue SUPPL. 1, 1996, Pages 6-12

  Cormican, Martin G ^a   Jones, Ronald N ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; BETA LACTAM ANTIBIOTIC; CIPROFLOXACIN; CLINAFLOXACIN; DALFOPRISTIN; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; EVERNIMICIN; EVERNINOMYCIN DERIVATIVE; GREPAFLOXACIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; METICILLIN; NOVOBIOCIN; OFLOXACIN; OXACILLIN; OXAZOLIDINEDIONE DERIVATIVE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINUPRISTIN; RIFAMPICIN; SITAFLOXACIN; SPARFLOXACIN; TEICOPLANIN; TROVAFLOXACIN; U 100572; UNCLASSIFIED DRUG; VANCOMYCIN;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIAL VIRULENCE; COAGULASE NEGATIVE STAPHYLOCOCCUS; ENTEROCOCCUS; GRAM POSITIVE BACTERIUM; HOSPITAL INFECTION; MINIMUM INHIBITORY CONCENTRATION; NEUTROPENIA; NONHUMAN; PENICILLIN RESISTANCE; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; STREPTOCOCCUS PYOGENES;

CROSS INFECTION; DRUG RESISTANCE, MICROBIAL; ENTEROCOCCUS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; INCIDENCE; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCUS; STREPTOCOCCUS;

BACTERIA (MICROORGANISMS); ENTEROCOCCUS; POSIBACTERIA; STAPHYLOCOCCI; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; STREPTOCOCCUS PYOGENES;

EID: 0029992202     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199600511-00004     Document Type: Article

References (38)

1. Schaberg DR, Culver DH, Gaynes RP. Major trends in the microbial etiology of nosocomial infection. Am J Med 1991; 91 Suppl. 3B: 725-55
2. Murray BE. The life and times of the Enterococcus. Clin Microbial Rev 1990; 3: 46-65
3. Moellering Jr RC. Emergence of Enterococcus as a significant pathogen. Clin Infect Dis 1992; 14: 1173-8
4. Jones RN, Kehrberg EN, Erwin ME, et al. Prevalence of important pathogens and antimicrobial activity of parenteral drugs at numerous medical centers in the United States. I. Study on the threat of emerging resistances: real or perceived? Diagn Microbiol Infect Dis 1994; 19: 203-15
5. Vincent JL, Bihari DJ, Suter PM, et al. The prevalence of nosocomial infection in intensive care units in Europe. JAMA 1995; 274: 639-44
6. Morrison D, Woodford N, Johnson A, et al. Review of acquired vancomycin resistance in enterococci submitted to a reference laboratory during a five year period (1988-1993) [abstract F2/5]. In: Program and Abstracts of the 3rd International Conference of the Hospital Infection Society (Book 1): London: Hospital Infection Society, 1994: 19
7. Swartz MN. Hospital acquired infections: diseases with increasingly limited therapies. Proc Natl Acad Sci 1994; 91: 2420-7
8. Archer GL, Climo MW. Antimicrobial susceptibility of coagulase-negative staphylococci. Antimicrob Agents Chemother 1994; 38: 2231-7
9. Kloos WE, Bannerman TL. Update on clinical significance of coagulase negative staphylococci. Clin Microbiol Rev 1994; 7: 117-40
10. Bochud DY, Eggiman P, Calandra T, et al. Bacteremia due to viridans streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors. Clin Infect Dis 1994; 18: 25-31
11. McCarthy AE, Victor G, Ramotar K, et al. Risk factors for acquiring ampicillin-resistant enterococci and clinical outcomes at a Canadian tertiary-care hospital. J Clin Microbiol 1994; 32: 2671-6
12. Jones RN, Sader HS, Erwin ME, et al. Emerging multiply resistant enterococci among clinical isolates. I. Prevalence data from 97 medical center surveillance study in the United States Diagn Microbiol Infect Dis 1995; 21: 85-93
13. Woodford N, Johnson AP, Morrison D, et al. Current perspectives on glycopeptide resistance. Clin Microbiol Rev 1995; 8: 585-615
14. Freeman C, Robinson A, Cooper B, et al. In vitro antimicrobial susceptibility of glycopeptide-resistant enterococci. Diagn Microbiol Infect Dis 1995; 21: 47-50
15. Cormican MG, Johnson DM, Jones RN. Activity of the quinupristin/dalfopristin combination (RP-59500; Synercid) testing against vancomycin-resistant Enterococci species. Diagn Microbiol Infect Dis 1996; 24: 59-60
16. Johnson CC, Slavoski L, Schwartz M, et al. In vitro activity of RP-59500 (quinupristin/dalfopristin) against antibiotic-resistant strains of Streptococcus pneumoniae and enterococci. Diagn Microbiol Infect Dis 1995; 21: 169-73
17. Sader HS, Pfaller MA, Tenover FC, et al. Evaluation and characterization of multiresistant Enterococcus faecium from 12 US medical centers. J Clin Microbiol 1994; 32: 2840-2
18. Ageles-Dominguez M, de Lencastre H, Linares J, et al. Spread and maintenance of a dominant methicillin-resistant Staphylococcus aureus (MRSA) clone during an outbreak of MRSA disease in a Spanish hospital. J Clin Microbiol 1994; 32: 2081-7
19. Jones RN, Barry AL, Gardiner RV, et al. The prevalence of staphylococcal resistance to penicillinase-resistant penicillins. A retrospective and prospective trial of isolates from 40 medical centers. Diagn Microbiol Infect Dis 1989; 12: 383-94
20. Archer GL, Auger P, Doern G, et al. RP-59500, a new streptogramin highly active against recent isolates of North American staphylococci. Diagn Microbiol Infect Dis 1993; 16: 223-6
21. Aldridge KE, Glefand MS, Schiro DO, et al. The rapid emergence of fluoroquinolone-methicillin-resistant Staphylococcus aureus infections in a community hospital. An in vitro look at alternative antimicrobial agents. Diagn Microbiol Infect Dis 1992; 15: 601-8
22. Chang SC, Hsiem WC, Luh KT. Fluoroquinolone resistance among methicillin-resistant staphylococci after usage of fluoroquinolones other than ciprofloxacin in Taiwan. Diagn Microbiol Infect Dis 1994; 19: 143-7
23. Blumberg H, Rimland P, Carroll DJ, et al. Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant Staphylococcus aureus. J Infect Dis 1991; 163: 1279-85
24. Utrup LJ, Kinlay JE, Rittenhouse SF, et al. Comparison of mupirocin susceptibility of nasal and non-nasal Staphylococcus aureus. Diagn Microbiol Infect Dis 1994; 20: 171-4
25. Layton MC, Evans Patterson J. Mupirocin resistance among consecutive isolates of oxacillin-resistant and borderline oxacillin-resistant Staphylococcus aureus at a university hospital. Antimicrob Agents Chemother 1994; 38: 1664-7
26. Noble WC, Virani Z, Cree RGA. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett 1992; 93: 195-8
27. Schwalbe RS, Stapleton JT, Gilligan PH. Emergence of vancomycin-resistance in coagulase-negative staphylococci. N Engl J Med 1987; 316: 927-31
28. Biovasco F, Giovanetti E, Montanari MP. Development of in vitro resistance to glycopeptide antibiotics: assessment in staphylococci of different species. J Antimicrob Chemother 1991; 27: 71-9
29. Barriere JC, Bouanchaud DH, Paris JM, et al. Antimicrobial activity against Staphylococcus aureus of semisynthetic injectable streptogramins: RP 59500 and related compounds. J Antimicrob Chemother 1992; 30 Suppl. A: 1-8
30. Aldridge KE, Schrio DD, Varner LM. In vitro antistaphylococcal activity and testing of RP 59500, a new streptogramin by two methods. Antimicrob Agents Chemother 1992; 36: 854-5
31. Brumfitt W, Hamilton-Miller JMT, Shah S. In vitro activity of RP-59500, a new semisynthetic streptogramin antibiotic, against Gram-positive bacteria. J Antimicrob Chemother 1992; 30: 29-37
32. Pechere JC. In vitro activity of RP-59500, a semisynthetic streptogramin, against staphylococci and streptococci. J Antimicrob Chemother 1992; 30 Suppl. A: 15-8
33. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. 6th International Supplement, M100-S6. Villanova, PA: NCCLS, 1995
34. Potgierter E, Carmichael M, Koornhoff HJ, et al. In vitro antimicrobial susceptibility of viridans streptococci isolated from blood cultures. Eur J Clin Microbiol Infect Dis 1992; 11: 543-6
35. Gomez-Garces JL, Alos JI, Cogollos R, Bacteriologic characteristics and antimicrobial susceptibility of 70 clinically significant isolates of Streptococcus milleri group. Diagn Microbiol Infect Dis 1994; 19: 68-73
36. Torres C, Reguera JA, SanMartin MJ, et al. van A-mediated vancomycin-resistant Enterococcus spp. in sewage. J Antimicrob Chemother 1994; 33: 553-61
37. Fass RJ. In vitro activity of RP-59500, a semisynthetic injectable pristinamycin against staphylococci, streptococci, and enterococci. Antimicrob Agents Chemother 1991; 35: 553-9
38. Verbist L, Verhaegen J. Comparative in vitro activity of RP-59500. J Antimicrob Chemother 1992; 30 Suppl. A: 39-44